170 related articles for article (PubMed ID: 30928770)
81. CEA to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with colorectal cancer peritoneal carcinomatosis undergoing cytoreduction surgery and intraperitoneal chemotherapy: A retrospective cohort study.
Kozman MA; Fisher OM; Rebolledo BJ; Parikh R; Valle SJ; Arrowaili A; Alzahrani N; Liauw W; Morris DL
J Surg Oncol; 2018 Mar; 117(4):725-736. PubMed ID: 29266235
[TBL] [Abstract][Full Text] [Related]
82. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer.
Manzanedo I; Pereira F; Pérez-Viejo E; Serrano Á; Hernández-García M; Martínez-Torres B; Rihuete-Caro C; Calzas J; Cueto M
Minerva Ginecol; 2017 Apr; 69(2):119-127. PubMed ID: 27415829
[TBL] [Abstract][Full Text] [Related]
83. The Impact of Early Recurrence on Quality of Life after Cytoreduction with HIPEC.
Hinkle NM; Botta V; Sharpe JP; Dickson P; Deneve J; Munene G
Am Surg; 2017 Jun; 83(6):633-639. PubMed ID: 28637567
[TBL] [Abstract][Full Text] [Related]
84. Peritoneal and extraperitoneal relapse after previous curative treatment of peritoneal metastases from colorectal cancer: What survival can we expect?
Gelli M; Huguenin JFL; de Baere T; Benhaim L; Mariani A; Boige V; Malka D; Sourouille I; Ducreux M; Elias D; Goéré D
Eur J Cancer; 2018 Sep; 100():94-103. PubMed ID: 30014885
[TBL] [Abstract][Full Text] [Related]
85. Cytoreduction and hyperthermic intraperitoneal chemotherapy: a feasible and effective option for colorectal cancer patients after emergency surgery in the presence of peritoneal carcinomatosis.
van Oudheusden TR; Braam HJ; Nienhuijs SW; Wiezer MJ; van Ramshorst B; Luyer MD; Lemmens VE; de Hingh IH
Ann Surg Oncol; 2014 Aug; 21(8):2621-6. PubMed ID: 24671638
[TBL] [Abstract][Full Text] [Related]
86. Oncologic Risk Stratification Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Appendiceal Carcinomatosis.
Wagner PL; Austin F; Zenati M; Jaech A; Mavanur A; Ramalingam L; Jones HL; Holtzman MP; Ahrendt SA; Zureikat AH; Pingpank JF; Zeh HJ; Bartlett DL; Choudry HA
Ann Surg Oncol; 2016 May; 23(5):1587-93. PubMed ID: 26744106
[TBL] [Abstract][Full Text] [Related]
87. Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy, Part II: Implementation.
Dunn D; Ciccarelli E; Moltzen N
AORN J; 2019 Dec; 110(6):606-625. PubMed ID: 31774172
[TBL] [Abstract][Full Text] [Related]
88. Hyperthermic intraperitoneal chemotherapy in colorectal cancer.
Fisher OM; Brown C; Esquivel J; Larsen SG; Liauw W; Alzahrani NA; Morris DL; Kepenekian V; Sourrouille I; Dumont F; Tuech JJ; Ceribelli C; Doussot B; Sgarbura O; Alhosni M; Quenet F; Glehen O; Cashin PH;
BJS Open; 2024 May; 8(3):. PubMed ID: 38722737
[TBL] [Abstract][Full Text] [Related]
89. Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Incidence, management and outcomes.
Valle SJ; Alzahrani N; Alzahrani S; Traiki TB; Liauw W; Morris DL
Surg Oncol; 2016 Sep; 25(3):315-20. PubMed ID: 27566038
[TBL] [Abstract][Full Text] [Related]
90. Early Postoperative Chemotherapy After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Isolated Peritoneal Carcinomatosis of Colon Cancer: A Multicenter Study.
Maillet M; Glehen O; Lambert J; Goere D; Pocard M; Msika S; Passot G; Elias D; Eveno C; Sabaté JM; Lourenco N; André T; Gornet JM;
Ann Surg Oncol; 2016 Mar; 23(3):863-9. PubMed ID: 26480848
[TBL] [Abstract][Full Text] [Related]
91. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Dissemination from Small Bowel Malignancy: Results from a Single Specialized Center.
Liu Y; Ishibashi H; Takeshita K; Mizumoto A; Hirano M; Sako S; Takegawa S; Takao N; Ichinose M; Yonemura Y
Ann Surg Oncol; 2016 May; 23(5):1625-31. PubMed ID: 26717938
[TBL] [Abstract][Full Text] [Related]
92. P.R.O.P.S. - A novel Pre-Operative Predictive Score for unresectability in patients with colorectal peritoneal metastases being considered for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Yong ZZ; Tan GHC; Shannon N; Chia C; Teo MCC
World J Surg Oncol; 2019 Aug; 17(1):138. PubMed ID: 31391066
[TBL] [Abstract][Full Text] [Related]
93. Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is Cure a Possibility?
Chia CS; You B; Decullier E; Vaudoyer D; Lorimier G; Abboud K; Bereder JM; Arvieux C; Boschetti G; Glehen O;
Ann Surg Oncol; 2016 Jun; 23(6):1971-9. PubMed ID: 26753751
[TBL] [Abstract][Full Text] [Related]
94. Poor outcome after cytoreductive surgery and HIPEC for colorectal peritoneal carcinomatosis with signet ring cell histology.
van Oudheusden TR; Braam HJ; Nienhuijs SW; Wiezer MJ; van Ramshorst B; Luyer P; de Hingh IH
J Surg Oncol; 2015 Feb; 111(2):237-42. PubMed ID: 25195780
[TBL] [Abstract][Full Text] [Related]
95. Peritoneal metastases from small bowel cancer: Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in The Netherlands.
van Oudheusden TR; Lemmens VE; Braam HJ; van Ramshorst B; Meijerink J; te Velde EA; Mehta AM; Verwaal VJ; de Hingh IH
Surgery; 2015 Jun; 157(6):1023-7. PubMed ID: 25818658
[TBL] [Abstract][Full Text] [Related]
96. The American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: An introduction of the peritoneal surface disease severity score.
Foster JM; Sleightholm R; Smith L; Ceelen W; Deraco M; Yildirim Y; Levine E; Muñoz-Casares C; Glehen O; Patel A; Esquivel J
J Surg Oncol; 2016 Dec; 114(7):779-784. PubMed ID: 27792292
[TBL] [Abstract][Full Text] [Related]
97. Applications of hyperthermic intraperitoneal chemotherapy for metastatic colorectal cancer.
Hornung M; Werner JM; Schlitt HJ
Expert Rev Anticancer Ther; 2017 Sep; 17(9):841-850. PubMed ID: 28715968
[TBL] [Abstract][Full Text] [Related]
98. Gains of Chromosome 1p and 15q are Associated with Poor Survival After Cytoreductive Surgery and HIPEC for Treating Colorectal Peritoneal Metastases.
Enblad M; Graf W; Terman A; Pucholt P; Viklund B; Isaksson A; Birgisson H
Ann Surg Oncol; 2019 Dec; 26(13):4835-4842. PubMed ID: 31620944
[TBL] [Abstract][Full Text] [Related]
99. The impact of molecular and mismatch repair status on the survival outcomes of surgically treated patients with colorectal peritoneal metastases.
Flood MP; Jain A; Mitchell C; Hewitt C; Ramsay R; Michael M; Heriot AG; Tie J
Eur J Surg Oncol; 2022 Oct; 48(10):2218-2225. PubMed ID: 35750576
[TBL] [Abstract][Full Text] [Related]
100. Exploring the prognostic and therapeutic utility of expanded mutation profiling in appendix peritoneal metastasis managed with CRS/HIPEC.
Zhang C; Plambeck BD; Craig ME; Tu A; Mikus RJ; Shostrom V; McDermott SP; Igbinigie I; Brown K; Cushman-Vokoun A; Foster JM
J Surg Oncol; 2021 Jun; 123(7):1599-1609. PubMed ID: 33667317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
